James Larkin
YOU?
Author Swipe
View article: Somatic evolution following cancer treatment in normal tissue
Somatic evolution following cancer treatment in normal tissue Open
The extent to which exogenous sources, including cancer treatment, contribute to somatic evolution in normal tissue remains unclear. Here we used high-depth duplex sequencing 1 (more than 30,000× coverage) to analyse 168 cancer-free sample…
View article: B-183 Teclistamab: a bispecific monoclonal IgG lambda therapeutic is observable on serum immunofixation and mass-fix
B-183 Teclistamab: a bispecific monoclonal IgG lambda therapeutic is observable on serum immunofixation and mass-fix Open
Background Monoclonal antibody therapies (t-mabs) are known to interfere in serum immunofixation, as they show up as a discrete band. Until recently, most of the t-mabs were IgG kappa monoclonal immunoglobulins, and laboratories were famil…
View article: B-123 Clinical Implication of Light Chain Fragmentation in Patients with Monoclonal Gammopathies
B-123 Clinical Implication of Light Chain Fragmentation in Patients with Monoclonal Gammopathies Open
Background The diagnosis of monoclonal gammopathies relies on the detection of monoclonal immunoglobulins (M-proteins) in serum or urine. Mass-Fix utilizes matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectro…
View article: Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review Open
We identified a need for robust data on intracranial and extracranial responses to systemic therapy in patients with RCC BrM+, taking into account prior local therapy exposure.
View article: Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study
Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study Open
Background/Objectives: Immune checkpoint inhibitors have significantly transformed the treatment paradigm of advanced melanoma, leading to substantial improvements in survival outcomes. However, this therapeutic success is accompanied by a…
View article: Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915 Open
Purpose CheckMate 915 ( NCT03068455 ) compared adjuvant nivolumab monotherapy versus combination nivolumab+ipilimumab in patients with resected stage III/IV melanoma. This exploratory analysis was performed to identify biomarkers that corr…
View article: A Bayesian Hierarchical Mixture Cure Modelling Framework to Utilize Multiple Survival Datasets for Long‐Term Survivorship Estimates: A Case Study From Previously Untreated Metastatic Melanoma
A Bayesian Hierarchical Mixture Cure Modelling Framework to Utilize Multiple Survival Datasets for Long‐Term Survivorship Estimates: A Case Study From Previously Untreated Metastatic Melanoma Open
Time to an event of interest over a lifetime is a central measure of the clinical benefit of an intervention used in a health technology assessment (HTA). Within the same trial, multiple end‐points may also be considered. For example, over…
View article: Supplementary File from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Supplementary File from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
MANIFEST Consortium List of Authors
View article: Data from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Data from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
Summary:Immunotherapy has revolutionized survival outcomes for many patients diagnosed with cancer. However, biomarkers that can reliably distinguish treatment responders from nonresponders, predict potential life-threatening and life-chan…
View article: Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
Notable large-scale immuno-oncology consortia formed in the recent era.
View article: Supplementary Table 2 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Table 2 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Supplementary Table 2. Changes in ssGSEA scores from normal kidney tissue to primary ccRCC tumor in normal-primary pairs.
View article: Supplementary Table 6 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Table 6 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Supplementary Table 6. Differential expression analysis by wGII of genes involved in cGAS-STING pathway.
View article: Supplementary Table 10 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Table 10 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Supplementary Table 10. Antibody and incubation procedure for immunohistochemistry (IHC) of CD3 and CD68.
View article: Supplementary Note 1 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Note 1 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Inputting information from previous TRACERx Renal studies
View article: Supplementary Table 9 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Table 9 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Supplementary Table 9. Univariate Cox regression results for progression-free survival in the TRACERx Renal cohort based on the expression of each of 613 HERV/LTR elements.
View article: Figure 3 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Figure 3 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Canonical ccRCC subclonal drivers and aneuploidy burden drive specific changes to the tumor transcriptome. A, Illustration of the procedure to analyze the transcriptional association of a subclonal copy number alteration without the confou…
View article: Supplementary Table 7 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Table 7 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Supplementary Table 7. TCR clones identified applying miXCR to bulk RNA-Sequencing data across 243 ccRCC and kidney-adjacent normal samples in TRACERx Renal.
View article: Figure 1 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Figure 1 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Transcriptional inter- and intratumor heterogeneity is pervasive in TRACERx Renal. A, UMAP visualizing the transcriptional variation across 231 tumor samples (gray points). Samples from patients K390, K243, and K153 are highlighted to illu…
View article: Figure 5 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Figure 5 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Spatial diversity of the TCR repertoire suggests heritable nature of the antigenic source in ccRCC. A, TCR and BCR similarity between pairs of samples across 60 TRACERx Renal patients with at least two regions sampled. Dark purple diamonds…
View article: Figure 2 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Figure 2 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Transcriptional evolution mirrors clonal structure and follows recurrent trends. A, Transcriptional distance between primary tumor samples and other primary tumor samples or adjacent normal kidney samples (12 patients with both available p…
View article: Supplementary Table 3 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Table 3 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Supplementary Table 3. Changes in ssGSEA scores from primary to metastasis in primary-metastasis pairs.
View article: Figure 6 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Figure 6 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Greater overall HERV expression, strongly associated with VHL loss of function, correlates with longer progression-free survival in ccRCC. A, Distribution in TRACERx Renal (n = 243 samples) of the median expression across 615 transcripts o…
View article: Supplementary Table 4 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Table 4 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Supplementary Table 4. 50 MSigDB hallmark signatures and corresponding categories.
View article: Supplementary Table 1 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Table 1 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Supplementary Table 1. Variance in gene expression for 16,716 genes passing expression filtering criteria in the TRACERx Renal study
View article: Supplementary Table 8 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Table 8 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Supplementary Table 8. BCR clones identified applying miXCR to bulk RNA-Sequencing data across 243 ccRCC and kidney-adjacent normal samples in TRACERx Renal.
View article: Supplementary Table 5 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Table 5 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Supplementary Table 5. Changes in ssGSEA scores from early to late clones.
View article: Figure 4 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Figure 4 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Heterogeneity of the TME in ccRCC. A, Association of TME cell abundance estimates from consensus TME and evolutionary trajectory of the tumor from which the sample is taken (in 171 primary tumor samples). Comparisons are one against all us…
View article: Supplementary Note 2 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Note 2 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Evaluation of the potential to reconstruct TCR repertiore from bulk RNA-Sequencing data
View article: Supplementary Table 11 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Supplementary Table 11 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal Open
Supplementary Table 11. Antibody / Opal combinations, dilutions and positions used for 6 biomarker immunofluorescence panel staining. RTU = Ready to Use.